RU2016144695A - Комплекс танната ситаглиптина - Google Patents
Комплекс танната ситаглиптина Download PDFInfo
- Publication number
- RU2016144695A RU2016144695A RU2016144695A RU2016144695A RU2016144695A RU 2016144695 A RU2016144695 A RU 2016144695A RU 2016144695 A RU2016144695 A RU 2016144695A RU 2016144695 A RU2016144695 A RU 2016144695A RU 2016144695 A RU2016144695 A RU 2016144695A
- Authority
- RU
- Russia
- Prior art keywords
- sitagliptin
- complex according
- dosage form
- oral dosage
- effective amount
- Prior art date
Links
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 title claims 12
- 229960004034 sitagliptin Drugs 0.000 title claims 12
- 241001000594 Tanna Species 0.000 title 1
- 229920002253 Tannate Polymers 0.000 claims 8
- 239000006186 oral dosage form Substances 0.000 claims 5
- 229940112822 chewing gum Drugs 0.000 claims 4
- 235000015218 chewing gum Nutrition 0.000 claims 4
- 239000003826 tablet Substances 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000012450 pharmaceutical intermediate Substances 0.000 claims 2
- 239000006188 syrup Substances 0.000 claims 2
- 235000020357 syrup Nutrition 0.000 claims 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims 1
- 239000001263 FEMA 3042 Substances 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000001055 chewing effect Effects 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000008123 high-intensity sweetener Substances 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims 1
- 229940033123 tannic acid Drugs 0.000 claims 1
- 235000015523 tannic acid Nutrition 0.000 claims 1
- 229920002258 tannic acid Polymers 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (15)
1. Комплекс танната ситаглиптина.
2. Комплекс танната ситаглиптина по п. 1, где содержание ситаглиптина составляет приблизительно от 25% до приблизительно 75% по массе.
3. Комплекс танната ситаглиптина по п. 2, где содержание ситаглиптина составляет приблизительно от 29% до приблизительно 33% по массе.
4. Комплекс танната ситаглиптина по п. 1, где отношение ситаглиптина к дубильной кислоте составляет приблизительно от 3:1 до приблизительно 1:4 по массе.
5. Комплекс танната ситаглиптина по п. 4, где отношение составляет приблизительно 2:1 по массе.
6. Фармацевтическая композиция, содержащая терапевтически эффективное количество комплекса танната ситаглиптина по п. 1 и инертный носитель.
7. Фармацевтическая композиция по п. 6, которая дополнительно содержит терапевтически эффективное количество дополнительного фармацевтически активного ингредиента.
8. Фармацевтический промежуточный продукт, который содержит терапевтически эффективное количество комплекса танната ситаглиптина по п. 1, фармацевтически приемлемый полимер и, необязательно, один или несколько полиолов, высокоинтенсивных подсластителей, ароматизаторов.
9. Пероральная дозированная форма, которая содержит фармацевтический промежуточный продукт по п. 8.
10. Пероральная дозированная форма по п. 9, которая находится в форме таблетки, капсулы, гранулы или порошка.
11. Пероральная дозированная форма по п. 9, которая находится в форме мягкой жвачки, медицинской жевательной резинки, жевательной таблетки, дезинтегрирующей таблетки, сиропа, саше, пероральной пленки, геля или лиосферы.
12. Пероральная дозированная форма по п. 9 с незначительным высвобождением в ротовой полости и немедленным высвобождение в желудке.
13. Пероральная дозированная форма по п. 12, которая представляет собой мягкую жвачку, медицинскую жевательную резинку, пероральную пленку, дезинтегрирующую таблетку или сироп.
14. Способ лечения, контроля или профилактики одного или нескольких заболеваний, при которых показан ингибитор DPP-IV, где способ включает введение терапевтически эффективного количества комплекса танната ситаглиптина по п. 1 нуждающемуся в этом пациенту.
15. Способ по п. 14, где заболевание представляет собой диабет 2 типа, ожирение или высокое артериальное давление.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461980641P | 2014-04-17 | 2014-04-17 | |
| US61/980,641 | 2014-04-17 | ||
| PCT/US2015/025504 WO2015160678A1 (en) | 2014-04-17 | 2015-04-13 | Sitagliptin tannate complex |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016144695A true RU2016144695A (ru) | 2018-05-21 |
| RU2016144695A3 RU2016144695A3 (ru) | 2018-10-11 |
| RU2696588C2 RU2696588C2 (ru) | 2019-08-05 |
Family
ID=54324454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016144695A RU2696588C2 (ru) | 2014-04-17 | 2015-04-13 | Комплекс танната ситаглиптина |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9833463B2 (ru) |
| EP (1) | EP3131631B1 (ru) |
| JP (1) | JP6523328B2 (ru) |
| KR (1) | KR102351813B1 (ru) |
| CN (1) | CN106456998B (ru) |
| AU (1) | AU2015247921B2 (ru) |
| BR (1) | BR112016023839A8 (ru) |
| CA (1) | CA2945681A1 (ru) |
| ES (1) | ES2932383T3 (ru) |
| MX (1) | MX2016013588A (ru) |
| RU (1) | RU2696588C2 (ru) |
| WO (1) | WO2015160678A1 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201818969A (zh) * | 2016-10-19 | 2018-06-01 | 日商帝化製藥股份有限公司 | 在生體內之藥物溶出控制用組成物 |
| US11096890B2 (en) | 2017-09-29 | 2021-08-24 | Merck Sharp & Dohme Corp. | Chewable dosage forms containing sitagliptin and metformin |
| WO2021199118A1 (ja) | 2020-03-30 | 2021-10-07 | 三菱電機株式会社 | エレベーター |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| US5663415A (en) | 1996-06-28 | 1997-09-02 | Jame Fine Chemicals, Inc. | Process for preparing antihistamine tannates |
| AR008789A1 (es) | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
| US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| AU749271B2 (en) | 1997-07-01 | 2002-06-20 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
| JP2002534512A (ja) | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドｇｌｐ−１アゴニスト |
| AU4537900A (en) | 1999-05-17 | 2000-12-05 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
| PE20010612A1 (es) | 1999-09-28 | 2001-07-12 | Bayer Corp | Agonistas del receptor 3 (r3) del peptido activador de la adenilato ciclasa de la pituitaria y su uso farmacologico |
| EP1401825B1 (en) | 2001-06-11 | 2009-08-05 | Virochem Pharma Inc. | Thiophene derivatives as antiviral agents for flavivirus infection |
| UA74912C2 (en) | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| US20030083354A1 (en) | 2001-10-26 | 2003-05-01 | Pediamed Pharmaceuticals, Inc. | Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions |
| US20030114535A1 (en) | 2001-12-14 | 2003-06-19 | Jame Fine Chemicals, Inc. | Dextrochlorpheniramine tannate |
| US6670370B1 (en) | 2001-12-14 | 2003-12-30 | Jame Fine Chemicals, Inc. | Dextromethorphan tannate |
| JO2625B1 (en) | 2003-06-24 | 2011-11-01 | ميرك شارب اند دوم كوربوريشن | Phosphoric acid salts of dipeptidyl betidase inhibitor 4 |
| JP2007504230A (ja) | 2003-09-02 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | ジペプチジルペプチダーゼ−ｉｖ阻害剤のリン酸塩の新規結晶性形態 |
| WO2005030127A2 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor |
| EP1708571A4 (en) | 2004-01-16 | 2009-07-08 | Merck & Co Inc | NEW CRYSTALLINE SALTS OF A DIPEPTIDYLPEPTIDASE IV HEMMER |
| US20050202050A1 (en) | 2004-03-12 | 2005-09-15 | Kiel Jeffrey S. | Single tank process for preparing tannate liquid and semi-solid dosage forms |
| EP1796671A4 (en) | 2004-09-15 | 2009-01-21 | Merck & Co Inc | AMORPHOUS FORM OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
| US20060270722A1 (en) * | 2005-05-31 | 2006-11-30 | Thornberry Nancy A | Combination of a dipeptidyl peptidase-IV inhibitor and a dual PPAR agonist for the treatment of diabetes and obesity |
| WO2007035198A2 (en) | 2005-07-25 | 2007-03-29 | Merck & Co., Inc. | Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor |
| WO2007050485A2 (en) * | 2005-10-25 | 2007-05-03 | Merck & Co., Inc. | Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension |
| ES2420124T3 (es) * | 2006-12-14 | 2013-08-22 | Teva Pharmaceutical Industries Ltd. | Sal de tanato de rasagilina |
| CA2708762A1 (en) | 2007-12-11 | 2009-06-18 | Conjuchem Biotechnologies Inc. | Formulation of insulinotropic peptide conjugates |
| US8003672B2 (en) * | 2008-04-21 | 2011-08-23 | Merck Sharp & Dohme Corp. | CB-1 receptor modulator formulations |
| EP2218721A1 (en) * | 2009-02-11 | 2010-08-18 | LEK Pharmaceuticals d.d. | Novel salts of sitagliptin |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
-
2015
- 2015-04-13 MX MX2016013588A patent/MX2016013588A/es active IP Right Grant
- 2015-04-13 JP JP2016562508A patent/JP6523328B2/ja active Active
- 2015-04-13 CA CA2945681A patent/CA2945681A1/en not_active Abandoned
- 2015-04-13 WO PCT/US2015/025504 patent/WO2015160678A1/en active Application Filing
- 2015-04-13 BR BR112016023839A patent/BR112016023839A8/pt not_active Application Discontinuation
- 2015-04-13 CN CN201580020211.4A patent/CN106456998B/zh active Active
- 2015-04-13 AU AU2015247921A patent/AU2015247921B2/en active Active
- 2015-04-13 RU RU2016144695A patent/RU2696588C2/ru active
- 2015-04-13 KR KR1020167028345A patent/KR102351813B1/ko active IP Right Grant
- 2015-04-13 ES ES15780045T patent/ES2932383T3/es active Active
- 2015-04-13 EP EP15780045.9A patent/EP3131631B1/en active Active
- 2015-04-13 US US15/302,211 patent/US9833463B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015247921A1 (en) | 2016-10-13 |
| JP2017511350A (ja) | 2017-04-20 |
| KR20160145008A (ko) | 2016-12-19 |
| MX2016013588A (es) | 2017-01-26 |
| CN106456998B (zh) | 2020-07-28 |
| ES2932383T3 (es) | 2023-01-18 |
| WO2015160678A1 (en) | 2015-10-22 |
| BR112016023839A2 (pt) | 2017-08-15 |
| US9833463B2 (en) | 2017-12-05 |
| EP3131631B1 (en) | 2022-11-16 |
| RU2696588C2 (ru) | 2019-08-05 |
| AU2015247921B2 (en) | 2019-07-11 |
| RU2016144695A3 (ru) | 2018-10-11 |
| US20170042922A1 (en) | 2017-02-16 |
| KR102351813B1 (ko) | 2022-01-18 |
| BR112016023839A8 (pt) | 2023-04-11 |
| CN106456998A (zh) | 2017-02-22 |
| JP6523328B2 (ja) | 2019-05-29 |
| EP3131631A4 (en) | 2017-11-29 |
| CA2945681A1 (en) | 2015-10-22 |
| EP3131631A1 (en) | 2017-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012236849A5 (ru) | ||
| JP2018507243A5 (ru) | ||
| JP2009501801A5 (ru) | ||
| EA200800881A1 (ru) | Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами | |
| JP2016164165A5 (ru) | ||
| RU2648760C3 (ru) | Фармацевтическая композиция, содержащая оксигидроксид железа, способ ее получения и применение | |
| JP2013541583A5 (ru) | ||
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| JP2017506624A5 (ru) | ||
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| WO2009127974A3 (ko) | 심혈관계 질환 치료용 약제학적 제제 | |
| AR084865A1 (es) | Preparacion de desintegracion rapida, comprimido dispersable por via oral | |
| RU2016143979A (ru) | Схема дозирования модулятора s1p с немедленным высвобождением | |
| NZ597534A (en) | Method for treating a patient in need of aspirin therapy | |
| JP2016507500A5 (ru) | ||
| JP2018039810A5 (ru) | ||
| JP2013536837A5 (ru) | ||
| RU2016144695A (ru) | Комплекс танната ситаглиптина | |
| JP2009522294A5 (ru) | ||
| JP2012505830A5 (ru) | ||
| JP2017511350A5 (ru) | ||
| RU2015143993A (ru) | Твердые лекарственные формы, обладающие противорвотным действием, с замедленным высвобождением | |
| JP2012041314A5 (ru) | ||
| WO2016074117A1 (zh) | 一种治疗肾虚的药物组合物及其制备方法 | |
| JP2017530142A5 (ru) |